Deborah Watkins Bruner on Side Effects From Platinum-Based Drugs in Ovarian Cancer

Throughout August, the FDA approved drugs for the treatment of diseases including non-small cell lung cancer, cutaneous T-cell lymphoma, astrocytoma/oligodendroglioma, and endometrial cancer.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Adding IMNN-001 to perioperative chemotherapy enhanced overall survival in patients with newly diagnosed, advanced ovarian cancer.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Findings from this study also demonstrate statistically meaningful improvements in breast cancer–specific quality of life and endocrine symptoms with acupuncture.

Adding dostarlimab to chemotherapy improved survival vs chemo alone in primary advanced or recurrent endometrial cancer.